All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL

October 7th 2023

The FDA has placed a partial clinical hold on investigational new drug application for lacutamab, leading to a pause in new patient enrollment for the phase 2 TELLOMAK trial and a phase 1b trial, which are evaluating the agent in patients with advanced cutaneous T-cell lymphoma and peripheral T-cell lymphoma, respectively.

Radiotherapy-Activated NBTXR3 Elicits Activity in Older/Comorbid Locally Advanced HNSCC

October 6th 2023

Treatment with the first-in-class radioenhancer NBTXR3 proved tolerable and effective in older patients with advanced head and neck squamous cell carcinoma and a comorbidity index.

FDA Panel Votes Sufficient Evidence Available to Support EFS Benefit of Eflornithine in Pediatric High-Risk Neuroblastoma

October 6th 2023

In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.

The Arsenal of Metastatic Breast Cancer Imaging Modalities Continues to Expand

October 6th 2023

Rena D. Callahan, MD, discusses the current standards for breast cancer imaging modalities, the complexities of using bone biopsy, and the importance of continuing to study nonstandard imaging modalities to increase the accessibility of breast cancer imaging for metastatic disease.

Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent Endometrial Cancer

October 6th 2023

The Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair-deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

October 6th 2023

A Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients with advanced non–small cell lung cancer and activating EGFR exon 20 insertion mutations has been submitted to the European Medicines Agency.

Florida Cancer Specialists & Research Institute Welcomes Bahaa Amer, MD and Savan Shah, MD to Statewide Practice

October 6th 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome hematologists and medical oncologists Bahaa Amer, MD and Savan Shah, MD to the statewide practice.

A Neurology-Oncology Fellowship That Provides a More “Boutique” Feel

October 6th 2023

Priya U. Kumthekar, MD, details the specialized program for fellows while reflecting on her own experiences, highlights her research in brain metastases, and offers advice to both fellowship directors and current fellows in oncology.

Elranatamab Represents Another Off-the-Shelf Option for Heavily Pretreated R/R Myeloma

October 6th 2023

Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and sheds light on the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment of this patient population.

BLA Resubmitted to FDA for On-Body Injector Presentation of Pegfilgrastim-cbqv

October 5th 2023

The biologics license application seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, a biosimilar of pegfilgrastim, has been resubmitted to the FDA for review.

Adjuvant Pembrolizumab Improves DFS in Localized Urothelial Cancer

October 5th 2023

Pembrolizumab as adjuvant therapy led to a statistically significant and clinically meaningful improvement in disease-free survival compared with observation in patients with localized muscle invasive urothelial cancer and locally advanced urothelial cancer.

First-Line Motixafortide Plus Cemiplimab/Chemotherapy Induces Responses in mPDAC

October 5th 2023

First-line treatment with the combination of motixafortide, cemiplimab-rwlc, gemcitabine, and nab-paclitaxel elicited responses in patients with metastatic pancreatic adenocarcinoma, according to initial data from the pilot portion of a phase 2 trial.

FDA Approves RAS Mutation Detection Kit as Companion Diagnostic for Panitumumab in mCRC

October 5th 2023

The FDA has approved the CRCdx® RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer, according to an announcement from EntroGen.

Fox Chase Cancer Center and Lewis Katz School of Medicine at Temple University Researchers Will Be Principal Investigators on a New Epidemiological Study of Asian Americans

October 5th 2023

Researchers from Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University will serve as two of the principal investigators on the Asian American Community Cohort and Equity Study, which is part of a new seven-year epidemiological cohort study of Asian Americans, Native Hawaiians, and Pacific Islanders.

Tips to Get Through Your Oncology Fellowship

October 5th 2023

Most fellows are incredibly busy and face emotional challenges as they navigate the path of cancer diagnosis to death with patients.

Cisplatin/Carboplatin Shortages Persist Across Majority of NCCN Cancer Centers

October 5th 2023

Shortages of cisplatin and carboplatin have continued at the majority of National Cancer Center Network (NCCN) institutions, according to data from a follow-up survey conducted by NCCN.

SABR to Oligoprogressive Lesions Delays Systemic Therapy Change in ER+ Advanced Breast Cancer

October 5th 2023

Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.

Reduced-Dose and Partial-Breast Radiotherapy Sustain Long-Term Safety and Efficacy in Early-Stage Breast Cancer

October 4th 2023

Treatment with reduced-dose or partial-breast radiotherapy sustained long-term safety and elicited similar rates of ipsilateral breast tumor relapse compared with whole-breast radiotherapy in patients with early-stage breast cancer.

Preoperative S-PBI Plus Endocrine Therapy is Safe, Produces Responses in Early-Stage ER+ Breast Cancer

October 4th 2023

Ablative preoperative stereotactic partial breast irradiation plus endocrine therapy was safe at a single fraction of 34 Gy and generated pathological complete responses and near complete responses in patients with early-stage, estrogen receptor-positive breast cancer.

AACR Highlights Advances and Challenges in Cancer Research in Newest Progress Report

October 4th 2023

The American Association for Cancer Research has published their annual Cancer Progress Report outlining recent advances in cancer research, remaining challenges in cancer care, and requests for the federal government to continue—and ideally increase—its investment in oncology.